Antipsychotics - Articles - Page 11

Managing Psychotropic Treatment with Foster Children

September 1, 2015

Joshua Feder, MD

In response to the rising use of psychotropic medications in Medicaid and foster care populations, some states, including California, have implemented specific guidelines. This article covers those guidelines with case examples.

The New Three-Month Version of Injectable Paliperidone: Should You Use It?

June 1, 2015

Michael Posternak, MD

Michael Posternak, MD Psychiatrist in private practice in Boston, MA

Patients with schizophrenia often stop taking their medications, so long-acting injectable antipsychotics (LAIs) are potentially good ways to make sure these patients have some medication in their systems over the long term.

Should You Be Monitoring Serum Levels of Atypical Antipsychotics in Kids?

May 1, 2015

For better or worse, we are prescribing atypical antipsychotics more frequently in children. Some of this is due to new FDA indications for kids (autism, psychotic disorders, and bipolar disorder), but much of the increase is driven by off-label use (Tourette’s, ADHD, OCD, depression, conduct disorder and impulse control disorders).

Saphris Approved for Pediatric Bipolar Disorder—What Do the Data Show?

April 1, 2015

In March 2015, the US Food and Drug Administration (FDA) approved Actavis’ asenapine (Saphris) for the acute treatment of manic or mixed episodes associated with bipolar disorder in kids between 10 and 17 years.

Latuda: An Evaluation of Its Usefulness

February 1, 2015

Daniel Carlat, MD

Daniel Carlat, MD Editor-in-Chief, Publisher, The Carlat Report. Dr. Carlat has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.

With nine other atypical antipsychotics already on the market (some of which are available as generics), did we really need another one? Given the pesky side effects of antipsychotics, maybe we did. Let’s take a look at what we know so far about Latuda (lurasidone) in an effort to figure out how to incorporate it into our clinical toolbox. Latuda was first approved by the US Food and Drug Administration (FDA) for use in schizophrenia in late 2010.

The New Emphasis on Community Functioning in Schizophrenia

February 1, 2015

Dost Ongur, PhD, MD and Daniel Carlat, MD

Dost Ongur, PhD, MD Chief, Psychotic Disorders Division, McLean Hospital, Belmont, MA Associate Professor of Psychiatry, Harvard Medical School Dr. Ongur has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity. Daniel Carlat, MD Editor-in-Chief, Publisher, The Carlat Report. Dr. Carlat has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.

Learn about the new emphasis on community functioning for patients with schizophrenia, in an interview with Dost Ongur, MD, PhD, chief of the psychotic disorders division at McLean Hospital and an associate professor of psychiatry at Harvard Medical School.

FDA Issues Alert for Geodon

February 1, 2015

In December 2014, the US Food and Drug Administration (FDA) issued a safety announcement warning that the antipsychotic drug ziprasidone (Geodon) has been associated with a rare but potentially fatal skin reaction.